Diffusion-weighted MRI of estrogen receptor-positive, HER2-negative, node-negative breast cancer: association between intratumoral heterogeneity and recurrence risk

被引:36
|
作者
Kim, Jin You [1 ,2 ]
Kim, Jin Joo [1 ]
Hwangbo, Lee [1 ]
Lee, Ji Won [1 ]
Lee, Nam Kyung [1 ]
Nam, Kyung Jin [3 ]
Choo, Ki Seok [3 ]
Kang, Taewoo [4 ]
Park, Heeseung [4 ]
Son, Yohan [5 ]
Grimm, Robert [6 ]
机构
[1] Pusan Natl Univ Hosp, Med Res Inst, Dept Radiol, Busan, South Korea
[2] Pusan Natl Univ, Dept Radiol, Sch Med, 1-10 Ami Dong, Busan 602739, South Korea
[3] Pusan Natl Univ, Dept Radiol, Yangsan Hosp, Yangsan, South Korea
[4] Pusan Natl Univ Hosp, Busan Canc Ctr, Busan, South Korea
[5] Siemens Healthineers Ltd, Seoul, South Korea
[6] Siemens Healthcare GmbH, Erlangen, Germany
关键词
Diffusion magnetic resonance imaging; Breast neoplasms; Oncotype DX; Recurrence; Biomarkers; ADJUVANT SYSTEMIC THERAPY; ONCOTYPE-DX; AMERICAN-SOCIETY; EARLY-STAGE; TUMOR HETEROGENEITY; GENE-EXPRESSION; COEFFICIENT; CHEMOTHERAPY; WOMEN; SURVIVAL;
D O I
10.1007/s00330-019-06383-6
中图分类号
R8 [特种医学]; R445 [影像诊断学];
学科分类号
1002 ; 100207 ; 1009 ;
摘要
Objectives To investigate possible associations between quantitative apparent diffusion coefficient (ADC) metrics derived from whole-lesion histogram analysis and breast cancer recurrence risk in women with estrogen receptor (ER)-positive, human epidermal growth factor receptor 2 (HER2)-negative, node-negative breast cancer who underwent the Oncotype DX assay. Methods This retrospective study was conducted on 105 women (median age, 48 years) with ER-positive, HER2-negative, node-negative breast cancer who underwent the Oncotype DX test and preoperative diffusion-weighted imaging (DWI). Histogram analysis of pixel-based ADC data of whole tumors was performed, and various ADC histogram parameters (mean, 5th, 25th, 50th, 75th, and 95th percentiles of ADCs) were extracted. The ADC difference value (defined as the difference between the 5th and 95th percentiles of ADCs) was calculated to assess intratumoral heterogeneity. Associations between quantitative ADC metrics and the recurrence risk, stratified using the Oncotype DX recurrence score (RS), were evaluated. Results Whole-lesion histogram analysis showed that the ADC difference value was different between the low-risk recurrence (RS < 18) and the non-low-risk recurrence (RS >= 18; intermediate to high risk of recurrence) groups (0.600 x 10(-3) mm(2)/s vs. 0.746 x 10(-3) mm(2)/s, p < 0.001). Multivariate regression analysis demonstrated that a lower ADC difference value (< 0.559 x 10(-3) mm(2)/s; odds ratio [OR] = 5.998; p = 0.007) and a small tumor size (<= 2 cm; OR = 3.866; p = 0.012) were associated with a low risk of recurrence after adjusting for clinicopathological factors. Conclusions The ADC difference value derived from whole-lesion histogram analysis might serve as a quantitative DWI biomarker of the recurrence risk in women with ER-positive, HER2-negative, node-negative invasive breast cancer.
引用
收藏
页码:66 / 76
页数:11
相关论文
共 50 条
  • [31] Safely Omitting Sentinel Lymph Node Biopsy in Women 70 Years Old with Early Stage, Clinically Node-Negative, Estrogen Receptor-Positive, HER2-negative Breast Cancer
    Seo, Dianne
    Sizer, Lina
    Roudakova, Kseniya
    Kjelstrom, Stephanie
    Carruthers, Catherine C.
    Carter, William B.
    Lamb, Elena
    Frazier, Thomas G.
    ANNALS OF SURGICAL ONCOLOGY, 2022, 29 (SUPPL 2) : 419 - 419
  • [32] PROGNOSTIC SIGNIFICANCE OF PgR EXPRESSION IN HORMONE-RECEPTOR POSITIVE, HER2-NEGATIVE, NODE-NEGATIVE BREAST CANCER
    Ono, Makiko
    Hitoshi, Tsuda
    Yoshida, Masayuki
    Shimizu, Chikako
    Kinoshita, Takayuki
    Tamura, Kenji
    ANNALS OF ONCOLOGY, 2014, 25
  • [33] Molecular essence and endocrine responsiveness of estrogen receptor-negative, progesterone receptor-positive, and HER2-negative breast cancer
    Yu, Ke-Da
    Jiang, Yi-Zhou
    Hao, Shuang
    Shao, Zhi-Ming
    BMC MEDICINE, 2015, 13
  • [34] Estrogen Receptor-Positive/HER2-Negative and Lymph Node-Negative Breast Cancers Have Similar Oncotype DX Recurrence Score Distribution and Prognosis in African American and Caucasian Patients
    Logan, Suzanna J.
    Zhang, Chao
    Liu, Yuan
    Siddiqui, Momin T.
    Cohen, Cynthia
    Li, Xiaoxian
    MODERN PATHOLOGY, 2017, 30 : 56A - 57A
  • [35] Tamoxifen and chemotherapy for lymph node-negative, estrogen receptor-positive breast cancer - Response
    Dignam, J
    Fisher, B
    JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE, 1998, 90 (06): : 468 - 469
  • [36] Estrogen Receptor-Positive/HER2-Negative and Lymph Node-Negative Breast Cancers Have Similar Oncotype DX Recurrence Score Distribution and Prognosis in African American and Caucasian Patients
    Logan, Suzanna J.
    Zhang, Chao
    Liu, Yuan
    Siddiqui, Momin T.
    Cohen, Cynthia
    Li, Xiaoxian
    LABORATORY INVESTIGATION, 2017, 97 : 56A - 57A
  • [37] Molecular essence and endocrine responsiveness of estrogen receptor-negative, progesterone receptor-positive, and HER2-negative breast cancer
    Ke-Da Yu
    Yi-Zhou Jiang
    Shuang Hao
    Zhi-Ming Shao
    BMC Medicine, 13
  • [38] Association between TP53 mutation and high 21-gene recurrence score in estrogen receptor-positive/HER2-negative breast cancer
    Jung Hwan Ji
    Soong June Bae
    Kyungsoo Kim
    Chihhao Chu
    Kyung-A Lee
    Yoonjung Kim
    Jee Hung Kim
    Joon Jeong
    Sung Gwe Ahn
    npj Breast Cancer, 8
  • [39] Association between TP53 mutation and high 21-gene recurrence score in estrogen receptor-positive/HER2-negative breast cancer
    Ji, Jung Hwan
    Bae, Soong June
    Kim, Kyungsoo
    Chu, Chihhao
    Lee, Kyung-A
    Kim, Yoonjung
    Kim, Jee Hung
    Jeong, Joon
    Ahn, Sung Gwe
    NPJ BREAST CANCER, 2022, 8 (01)
  • [40] A retrospective study of 21-gene recurrence score assay compared with clinicopathological markers in node-negative, hormone receptor-positive, HER2-negative breast cancer.
    Chen, Junqing
    Wang, Xiaojia
    Chen, Zhanhong
    JOURNAL OF CLINICAL ONCOLOGY, 2017, 35